• MaxCyte Inc MXCT.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -9 cents. The mean expectation of six analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -11 cents to -9 cents per share.

• Revenue fell 18.4% to $8.51 million from a year ago; analysts expected $9.53 million.

• MaxCyte Inc's reported EPS for the quarter was a loss of 12 cents​.

• The company reported a quarterly loss of $12.36 million.

• MaxCyte Inc shares had fallen by 5.5% this quarter and lost 50.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

• Wall Street's median 12-month price target for MaxCyte Inc is $6.50, about 68.6% above its last closing price of $2.04

This summary was machine generated from LSEG data August 6 at 10:36 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)